Incorporated in 1984 and headquartered in Hyderabad, Neuland Laboratories has evolved over four decades from a domestic bulk-drug manufacturer into a global API Contract Development and Manufacturing Organization (CDMO) serving over 500 pharmaceutical and biotech customers across 80+ countries. The company operates from three USFDA-inspected manufacturing units (Bonthapally, Pashamylaram, Gaddapotharam) plus a dedicated R&D centre, and employs roughly 2,000 people. It is promoted and controlled by the Davuluri family through the Davuluri Ownership Trust.

Neuland runs two core business verticals. Generic Drug Substances (GDS) comprises Prime APIs — roughly 15 mature, large-volume, highly competitive molecules such as Levetiracetam (anti-epileptic) and Mirtazapine (anti-depressant) — alongside a smaller book of higher-value Specialty APIs. Custom Manufacturing Solutions (CMS) is the growth engine: Neuland partners with innovator biotech and pharma companies to develop and commercially manufacture new chemical entities (NCEs) and advanced intermediates across the clinical lifecycle, increasingly including peptide synthesis, where a new dedicated facility is being built out.

The CMS mix shift is the central investment narrative. CMS revenue share has risen from roughly 30% in FY22 to about half of sales by FY24-26, driving a step-change in blended margins as CMS carries materially better economics than commoditised Prime APIs. The most visible recent catalyst is Neuland’s role as a manufacturing partner in the supply chain for Cobenfy (xanomeline/trospium chloride), a USFDA-approved schizophrenia therapy — a commercial CMS molecule that, together with a new Gland Pharma-backed sterile API manufacturing tie-up, has driven an exceptional run of quarterly results through FY26 and into Q1 FY27.

Growth has been anything but linear. FY25 saw a margin dip (22% OPM) as the mix normalised after an unusually strong FY24, before FY26 and the trailing twelve months re-accelerated sharply on the back of CMS commercial ramp-up — TTM sales growth of 78% and profit growth of 278% are the standout, if unsustainable-at-this-pace, numbers in the ten-year history. Balance sheet: net worth stands at roughly ₹1,875 Cr (FY26) against total assets of ₹2,930 Cr, with borrowings of ₹301 Cr — a comfortably low-leverage structure. Cash conversion cycle remains elevated at ~214 days (FY26), reflecting long API/CMS inventory and receivable cycles, and FY26 free cash flow was negative (-₹50 Cr) as capex ramped for capacity and the new peptide facility.

A 10-year explicit FCF projection is built off the TTM base (Sales ₹2,372 Cr), assuming growth tapering from 30% in Yr1 to 6% by Yr10 as the CMS ramp normalises, EBITDA margin expanding from 31% to 34% as scale builds, and capex intensity easing from ~8% to 5% of sales as the current expansion cycle completes. WACC of 12% and terminal growth of 5% are used per house convention.

At the CMP of ₹23,550, the stock trades roughly 80% above the base-case DCF fair value — a gap that only closes if growth and margins run meaningfully hotter, and for far longer, than the already-generous assumptions above. This is the single most important number in this report: intrinsic-value investors should treat DCF as a floor-check, not a target.

On P/E, Neuland actually sits at the lower end of the CDMO/API peer set — Laurus Labs and Suven both trade near 95x versus Neuland’s 60.7x. Applying a peer-anchored multiple range of 50x-65x to TTM EPS of ₹388 implies a fair value band of roughly ₹19,400-₹25,200, comfortably bracketing the CMP. On EV/EBITDA (illustrative sector multiple ~30-35x against TTM EBITDA of ₹763 Cr) fair value works out to roughly ₹18,900-₹20,600/share. Relative valuation is therefore far more forgiving of the current price than the DCF — the market is essentially pricing Neuland in line with, or at a discount to, higher-growth CDMO peers.

Book value stands at ₹1,461/share (FY26), against which the stock trades at 16.1x — an asset-based floor of limited relevance for a business whose value is overwhelmingly driven by intangible process know-how, regulatory dossiers, and customer relationships rather than tangible net assets. Net fixed assets plus CWIP of ~₹1,388 Cr (largely the three manufacturing units and the peptide facility under construction) represent the productive core, but NAV should be read only as a distress-scenario reference point, not a valuation anchor.

EPV strips out growth assumptions entirely and asks what the current, sustainable earnings stream is worth in perpetuity. Using a normalised TTM EBIT of ~₹664 Cr, post-tax NOPAT of ~₹491 Cr, and capitalising at the 12% WACC (no reinvestment for growth) gives a firm value of ~₹4,092 Cr, or roughly ₹2,995/share of equity value after adjusting for net debt.

The wide gap between EPV (₹2,995) and CMP (₹23,550) simply confirms that almost none of today’s price reflects “current earnings held flat” — the entire valuation case rests on CMS/peptide capacity additions converting into a durably larger and higher-margin earnings base over the coming years, not on what Neuland earns today.

SOTP value works out to roughly ₹21,067/share — segment PAT splits are estimated (Neuland does not disclose full segment-level P&L) based on disclosed revenue mix and CMS’s superior margin profile. This method, which explicitly rewards the CMS franchise with a CDMO-grade multiple while holding the mature GDS book to a generic-API multiple, comes closest of all methods here to justifying a price near the current CMP.

The buy range is anchored to a blend of DCF (₹13,075), EPV (₹2,995, as a deep floor only) and the relative-valuation band (₹19,400-25,200), with the fair-value ceiling set where peer-multiple and DCF-implied prices begin to converge. At the CMP of ₹23,550, Neuland sits above this fair-value zone.

A disciplined entry would look for either (a) a broad small-cap pharma correction that pulls the stock back into the ₹15,000-19,000 accumulate band, or (b) two-to-three quarters of confirmed, sustained CMS commercial-molecule revenue (rather than the current lumpy, project-driven ramp) that would justify underwriting a structurally higher earnings base and paying up for it. Averaging in in tranches rather than taking a full position at any single price point suits a stock with this much embedded optimism.

The CMP of ₹23,550 already sits inside the “Reduce” zone on this framework — existing holders with large embedded gains (the stock is up ~79% over the past year and has delivered a 10-year price CAGR of 37%) may consider trimming into strength rather than adding.

Note the tension with Section 3: a forward-earnings lens (which the market typically uses for growth stocks) is far more constructive than the DCF, because it implicitly re-rates the multiple rather than discounting cash flows back to today. Whether Neuland “deserves” a 45-60x forward multiple in three years is ultimately a judgment on the durability of the CMS franchise, not a mechanical valuation exercise.

Shareholding Trend (%)

Top 10 Named Institutional Investors / Fund Houses

Named holdings are drawn from the most recent publicly disclosed shareholding filings (largely Mar’25-Jun’26 quarters) reported via exchange disclosures and shareholding-pattern data; individual line-item percentages shift every quarter and are not all disclosed at the same cut-off date, so treat the ranking as directional. Malabar India Fund’s holding, for instance, was cut from 7.18% to 5.06% via an open-market sale disclosed on 17 Aug 2026.

Promoter Entity Breakup

Ownership trends tell a coherent story: promoter holding has steadily declined from 36% to 32.6% over three years — not alarming in isolation, but worth watching alongside the near-total absence of pledging. The far more important trend is the sharp rise in domestic institutional ownership, from under 7% in late 2023 to over 16% by mid-2026, even as marquee FPI names like Malabar India Fund have been trimming. In effect, domestic mutual funds and insurers have been the incremental buyer absorbing both promoter and select FII selling — a rotation that has provided a steady bid under the stock through its re-rating, but also means a larger, more price-sensitive domestic institutional base to satisfy going forward.